Jesus, Sanchez-RuizMiguel, Quintela-Fandino. (2015) Targeting the Tumor Stroma in Breast Cancer. Current Breast Cancer Reports 7 , 71-79 /Sanchez-Ruiz J,Quintela-Fandino M.Targeting the tumor stroma in breast cancer[J].Curr Breast Cancer Rep,2015,7(1):71-79....
P. Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). Curr. Oncol. Rep. 19, 47 (2017). Article PubMed CAS Google Scholar Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell ...
BackgroundOncolytic virus (OV)-based therapies have an emerging role in the treatment of solid tumors, involving both direct cell lysis and immunogenic cell death. Nonetheless, tumor-associated stroma limits the efficacy of oncolytic viruses by forming a barrier that blocks efficient viral penetration...
On in vivo examination, CAFs promoted tumor progression, and PFD suppressed tumor progression with an inhibitory effect on tumor-stroma crosstalk. PFD might inhibit not only fibroblast activity, but also the crosstalk between cancer cells and fibroblasts. PFD may have great potential as a novel ...
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2014;2:867-77.Schrand B. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conju- gat...
Tumor-associated macrophages are an abundant cell type in the tumor microenvironment. These macrophages serve as a promising target for treatment of cancer due to their roles in promoting cancer progression and simultaneous immunosuppression. The TAM receptors (Tyro3, Axl and MerTK) are promising thera...
immune evasion and suppression mechanisms, including attracting a highly suppressive cell and cytokine repertoire in the tumor stroma [5] and inducing anergy, exhaustion or deletion of tumor antigen-specific T cells [6], [7], [8], even when anti-tumor effector T cells are circulating ...
Among these are therapies that reduce the tumor stroma, allowing for a more effective delivery of conventional therapeutics to the cancer cells; antibodies that activate a macrophage-mediated immune response to the tumor and overcome its immunosuppressive environment; and inhibitors of signaling pathways ...
Tumour necrosis factor: strategies for improving the therapeutic index. J Drug Target, 5: 403-413, 1998... Corti,Marcucci - 《Journal of Drug Targeting》 被引量: 31发表: 1998年 Clinical use of therapies targeting tumor vasculature and stroma. Many recent advances in cancer therapy have been ...
et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178–690 (2010). Article CAS Google Scholar Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl....